Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:VTYX 23 October 2025 - 7 January 2026

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14

Eli Lilly agreed to acquire Ventyx Biosciences for $14 per share in cash, valuing the company at about $1.2 billion. Ventyx shares closed up 37% at $13.81, while Lilly rose 4%. The deal is expected to close in the first half of 2026, pending shareholder approval. Investors await proxy filings and Lilly’s next earnings call for further details.
7 January 2026
···
Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Ventyx Biosciences (VTYX) Stock Rockets on Breakthrough Inflammation Study – Analysts Bullish

Ventyx Biosciences shares surged about 85% in after-hours trading Oct. 22, closing at $7.15 after positive Phase 2 trial results for its NLRP3 inhibitor. The drug showed an 80% drop in hsCRP, a key inflammation marker, in obese patients with heart risk factors. VTX3232 was well tolerated and did not cause weight loss. Wall Street analysts set average 12-month price targets near $7.50, with some as high as $21.
23 October 2025
·
Go toTop